Down’s syndrome (Trisomy 21) is usually asymptomatic and is usually detected during prenatal diagnosis during pregnancy. Fetal aneuploidy screening should be performed in the middle trimester at 14 to 19+6 weeks of gestation. Interventional prenatal diagnosis should be performed if the Down’s syndrome screening suggests a high risk, or if the non-invasive prenatal test suggests a critical risk or above. Amniocentesis technology is widely used, and if the result suggests that the fetus is with trisomy 21, then it will be Down’s child, and there are usually no obvious symptoms. At present, the State attaches great importance to Down’s syndrome screening, and reimbursement can be made to women who are eligible to give birth, with an accuracy rate of about 60%. For women who seek a higher accuracy rate or who are not suitable for Down’s syndrome screening, prenatal non-invasive DNA prenatal testing is feasible, and amniocentesis is recommended for women who want to undergo prenatal screening, so it is recommended that regular obstetric checkups be conducted during pregnancy, and that appropriate screening methods be selected under the guidance of the physician.